Serum MIC-1, LMTK-3 and IGFBP-7 levels in the prognosis of lung cancer treated with ablation combined with chemotherapy
Serum MIC-1, LMTK-3 and IGFBP-7 levels in lung cancer
Abstract
Objective To explore the value of the serum levels of macrophage inhibitory factor 1 (MIC-1), Lemur tyrosine kinase 3 (LMTK-3), and insulin-like growth factor binding protein 7 (IGFBP-7) in the prognosis assessment of patients with advanced lung cancer treated with ablation combined with chemotherapy.
Methods 190 patients with advanced lung cancer who received care at this hospital between January 2022 and June 2024 were chosen to be part of the lung cancer group. The healthy control group consisted of 90 healthy people who attended the hospital and had physical tests over the same time period. Percutaneous microwave thermal ablation treatment was used to treat every patient with advanced lung cancer, and chemotherapy was administered within one week after treatment. The levels of serum MIC-1, LMTK-3 and IGFBP-7 before and after treatment and before treatment in patients with different therapeutic effects in the lung cancer group and the healthy control group were compared. Univariate and multivariate analyses were conducted on the factors affecting the prognosis of patients to analyze the efficacy of serum MIC-1, LMTK-3 and IGFBP-7 levels in predicting the prognosis of patients with advanced lung cancer.
Results Serum MIC-1 and LMTK-3 levels in the lung cancer group were substantially higher than those in the healthy control group both before and after therapy (P<0.05). Serum MIC-1 and LMTK-3 levels in the lung cancer group were much lower after therapy than they were before, and the difference was statistically significant (P<0.05). The serum IGFBP-7 level in the lung cancer group before and after treatment was significantly lower than that in the healthy control group (P<0.05). After treatment, the serum IGFBP-7 level in the lung cancer group was significantly greater than that before treatment (P<0.05). Patients with lung cancer experienced 29 cases of stable response (SD)+ progressive response (PD) and 66 cases of complete response (CR)+ partial response (PR) following treatment. Those with SD+PD advanced lung cancer had significantly higher blood MIC-1 and LMTK-3 levels prior to treatment than those with CR+PR advanced lung cancer. The serum IGFBP-7 level of advanced lung cancer patients with SD+PD before treatment was significantly lower than that of advanced lung cancer patients with CR+PR. In patients with advanced lung cancer, elevated blood MIC-1 and LMTK-3 levels and lower IGFBP-7 levels prior to treatment were independent risk factors for death within a year following treatment (P<0.05). The combined detection of the serum MIC-1, LMTK-3 and IGFBP-7 levels for the prediction of death within one year after treatment for advanced lung cancer had a sensitivity of 91.3%, a specificity of 95.8%, and an AUC of 0.974. Its AUC was significantly greater than that of MIC-1 (Z=2.378, P=0.017) and LMTK-3 (Z=2.897). The AUC was detected separately for IGFBP-7 (Z=3.213, P=0.001), however, the AUC for each of the three indicators did not differ statistically significantly (P>0.05)..
Conclusion Important markers for assessing the effectiveness of chemotherapy and ablation in the treatment of advanced lung cancer are serum MIC-1, LMTK-3, and IGFBP-7. With the help of combination detection, the prognosis of patients with advanced lung cancer after therapy can be predicted.
References
2.Greer JA, Post KE, Chabria R, Aribindi S, Brennan N, Eche-Ugwu IJ, Halpenny B, Fox E, Lo S, Waldman LP, Pintro K, Rabideau DJ, Pirl WF, Cooley ME, Temel JS. Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer. J Clin Oncol. 2024 Oct 20;42(30):3570-3580. doi: 10.1200/JCO.24.00048. Epub 2024 Aug 1. PMID: 39088766; PMCID: PMC11483213.
3.Sen T, Takahashi N, Chakraborty S, Takebe N, Nassar AH, Karim NA, Puri S, Naqash AR. Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nat Rev Clin Oncol. 2024 Aug;21(8):610-627. doi: 10.1038/s41571-024-00914-x. Epub 2024 Jul 4. PMID: 38965396; PMCID: PMC11875021.
4.Reuss JE, Rosner S, Levy BP. Antibody‒drug conjugates in advanced lung cancer: Is this a new frontier? Clin Adv Hematol Oncol. 2024 Jun;22(5):217-226. PMID: 38805313.
5.Presley CJ, Dalal N, Davenport AP, Gounden A, Ramchandran K, Tonorezos E. Survivorship in Advanced Lung Cancer: Understanding a New Landscape and Opportunities. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433298. doi: 10.1200/EDBK_433298. PMID: 38768420.
6.Xue H, Chen Y, Zhou Y. Radioimmunotherapy: a game-changer for advanced non-small cell lung cancer. Front Immunol. 2024 Dec 6;15:1522508. doi: 10.3389/fimmu.2024.1522508. PMID: 39712010; PMCID: PMC11659256.
7.Loh J, Low JL, Sachdeva M, Low PQ, Wong RSJ, Huang Y, Chia PL, Soo RA. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(9):913-926. doi: 10.1080/14737140.2023.2245140. Epub 2023 Aug 13. PMID: 37551698.
8.Solta A, Ernhofer B, Boettiger K, Megyesfalvi Z, Heeke S, Hoda MA, Lang C, Aigner C, Hirsch FR, Schelch K, Döme B. Small cells - big issues: biological implications and preclinical advancements in small cell lung cancer. Mol Cancer. 2024 Feb 24;23(1):41. doi: 10.1186/s12943-024-01953-9. PMID: 38395864; PMCID: PMC10893629.
9.Tsukada A, Morita C, Shimizu Y, Uemura Y, Naka G, Takasaki J, Nokihara H, Izumi S, Hojo M. Efficacy of first-line immune checkpoint inhibitor and anti-angiogenic agent combination therapy for Kirsten rat sarcoma viral antigen-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis. Thorac Cancer. 2024 Sep;15(25):1854-1862. doi: 10.1111/1759-7714.15413. Epub 2024 Jul 31. PMID: 39086088; PMCID: PMC11367661.
10.Baladi A, Tafenzi HA, Zouiten O, Afani L, Essaadi I, El Fadli M, Belbaraka R. Immunotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: Challenges and Perspectives. Int J Mol Sci. 2025 Feb 27;26(5):2120. doi: 10.3390/ijms26052120. PMID: 40076743; PMCID: PMC11899869.
11.Yu L, Wang R, Zhao Y, Wu Y, Wang L, Chen H, He Z, Wang Q, Wu Y. Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Non-small Cell Lung Cancer. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231168466. doi: 10.1177/15330338231168466. PMID: 37078129; PMCID: PMC10126640.
12.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852. doi: 10.18632/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137.
13.Kundu M, Dey A, Dasgupta S. Replication stress response and radioresistance in lung cancer: Mechanistic insights and advanced therapeutic approaches. Curr Probl Cancer. 2025 Jun;56:101206. doi: 10.1016/j.currproblcancer.2025.101206. Epub 2025 Apr 22. PMID: 40267631.
14.Melosky B, Vincent MD, McGuire AL, Brade AM, Chu Q, Cheema P, Martins I, Spicer JD, Snow S, Juergens RA. Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer. Int J Cancer. 2024 Sep 15;155(6):963-978. doi: 10.1002/ijc.35031. Epub 2024 Jun 20. PMID: 38900018.
15.Lee S, Park S, Lee HY, Jeon H, Lee S, Choi S, Eo W. A potential treatment option for advanced non-small cell lung cancer: Three cases. Explore (NY). 2023 May-Jun;19(3):453-457. doi: 10.1016/j.explore.2022.04.001. Epub 2022 Apr 5. PMID: 35431108.
16.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248. doi: 10.3390/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572.
17.Gridelli C, Attili I, Bennati C, Bironzo P, Bria E, Cortinovis DL, Soto Parra H, de Marinis F. Immunotherapy in advanced non-small cell lung cancer: What to do for the 'Invisible' patients after IPSOS trial results? Lung Cancer. 2025 Apr;202:108482. doi: 10.1016/j.lungcan.2025.108482. Epub 2025 Mar 7. PMID: 40086027.
18.Simone CB 2nd. Enhancing Outcomes in Locally Advanced Non-Small Cell Lung Cancer Through Stereotactic Dose Escalation. Int J Radiat Oncol Biol Phys. 2024 Nov 1;120(3):695-697. doi: 10.1016/j.ijrobp.2024.06.036. Epub 2024 Sep 24. PMID: 39326955.
19.Buma AIG, Schuurbiers MMF, van Rossum HH, van den Heuvel MM. Clinical perspectives on serum tumor marker use in predicting prognosis and treatment response in advanced non-small cell lung cancer. Tumor Biol. 2024;46(s1):S207-S217. doi: 10.3233/TUB-220034. PMID: 36710691.
20.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861. doi: 10.3390/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220.
21.Opalikhin A, Friedland S, Madariaga ML, Owen DH, Besse B. Surgical and Perioperative Advances for Patients With Locally Advanced Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e481060. doi: 10.1200/EDBK-25-481060. Epub 2025 Jun 12. PMID: 40505076.
22.Lobinger D, Hiebinger A, Eicher F, Groß G, Shalabi I, Reiche A, Bodner J. Rescue surgery in palliative indication as last therapeutic option for complicated advanced stage lung cancer. Eur J Surg Oncol. 2023 Dec;49(12):107253. doi: 10.1016/j.ejso.2023.107253. Epub 2023 Oct 31. PMID: 37944369.
23.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603. doi: 10.1097/CAD.0000000000001189. PMID: 34338240; PMCID: PMC8670349.
24.Khan SR, Breadner D. Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small Cell Lung Cancer Treatment. Curr Oncol. 2025 Mar 31;32(4):206. doi: 10.3390/curroncol32040206. PMID: 40277763; PMCID: PMC12025875.
25.Kearns E, Chu AK, Nissim R, Wheatley-Price P, Aubry T, Lebel S. The Supportive Care Needs of Individuals Living With Advanced or Metastatic Lung Cancer Receiving Targeted or Immunotherapies. Psychooncology. 2024 Nov;33(11):e70015. doi: 10.1002/pon.70015. PMID: 39472304.
26.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
27.Durbin L, Murali B, Li S, Hawthorne S, Clark O. Treatment patterns in advanced/metastatic non-small cell lung cancer in China: results from the CancerMPact® survey 2021. Future Oncol. 2024;20(19):1319-1331. doi: 10.2217/fon-2023-0469. Epub 2024 May 2. PMID: 38695478; PMCID: PMC11321399.
28.Gautam Roy P, Reingold D, Pathak N, Verma S, Gupta A, Meti N, Molto C, Malik PS, Linford G, Mittal A. Recent Advances in the Management of EGFR-Mutated Advanced Non-Small Cell Lung Cancer-A Narrative Review. Curr Oncol. 2025 Aug 9;32(8):448. doi: 10.3390/curroncol32080448. PMID: 40862817; PMCID: PMC12384734.
29.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
30.Zhang YR, Lu YH, Lin CM, Ku JW. Pretreatment CT Texture Analysis for Predicting Survival Outcomes in Advanced Non-small Cell Lung Cancer Patients Receiving Immunotherapy: A Systematic Review and Meta-Analysis. Thorac Cancer. 2025 Aug;16(15):e70144. doi: 10.1111/1759-7714.70144. PMID: 40755255; PMCID: PMC12320133.
31.Deaths from advanced lung cancer have dropped significantly since immunotherapy became standard-of-care. Saudi Med J. 2024 Oct;45(10):1200. PMID: 39379112; PMCID: PMC11463563.
32.Meng Y, Zhu M, Yang J, Wang X, Liang Y, Yu M, Li L, Kong F. Treatment Advances in Lung Cancer with Leptomeningeal Metastasis. Curr Cancer Drug Targets. 2024;24(9):910-919. doi: 10.2174/0115680096276133231201061114. PMID: 38279718.
33.Roberts HN, Solomon B, Harden S, Lingaratnam S, Alexander M. Utility of 30-Day Mortality Following Systemic Anti-Cancer Treatment as a Quality Indicator in Advanced Lung Cancer. Clin Lung Cancer. 2024 Jul;25(5):e211-e220.e1. doi: 10.1016/j.cllc.2024.04.001. Epub 2024 Apr 6. PMID: 38772809.
34.Moretti M, Wellekens S, Dirkx S, Vekens K, Van Laethem J, Ilsen B, Vanderhelst E. Features of postobstructive pneumonia in advanced lung cancer patients, a large retrospective cohort. Infect Dis (Lond). 2023 Feb;55(2):149-157. doi: 10.1080/23744235.2022.2143888. Epub 2022 Nov 11. PMID: 36369872.
35.Chen SY, Wang CT, Huang TH, Tsai JL, Wang HT, Yen YT, Tseng YL, Wu CL, Chang JM, Shiau AL. Advancing Lung Cancer Treatment with Combined c-Met Promoter-Driven Oncolytic Adenovirus and Rapamycin. Cells. 2024 Sep 23;13(18):1597. doi: 10.3390/cells13181597. PMID: 39329778; PMCID: PMC11430802.
36.Sato S, Sezaki R, Shinohara H. Significance of preoperative evaluation of modified advanced lung cancer inflammation index for patients with resectable non-small cell lung cancer. Gen Thorac Cardiovasc Surg. 2024 Aug;72(8):527-534. doi: 10.1007/s11748-023-02003-9. Epub 2024 Jan 22. PMID: 38246904.
Copyright (c) 2025 Yilin Fu, Lifeng Shi, Quanxin Lu, Fatao Yu, Xiaofeng Hong, Guoliang Zeng, Meng Li
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.